1. Continued consideration for high dose influenza vaccine in persons living with HIV
- Author
-
Joshua R. Sawyer, Raymond Cha, Jessica Swiderek, and Sin-Ling Jennings
- Subjects
0301 basic medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Influenza vaccine ,business.industry ,Virology ,Human immunodeficiency virus (HIV) ,medicine ,030212 general & internal medicine ,medicine.disease_cause ,business - Abstract
High dose-inactivated influenza vaccine (HD IIV3) is currently recommended only for patients who are 65 or older, whereas other potential risk groups, such as people living with HIV, are excluded from this recommendation. There is a potential that persons living with HIV may be at an increased risk of complications secondary to influenza. HD IIV3 has been associated with increased rates of seroconversion, seroprotection and hemagglutinin inhibition geometric mean titers in comparison to standard dose-inactivated influenza vaccine in this population. Despite the major impact that combination antiretroviral therapy has on this population, further consideration of HD IIV3 may be valuable until virological suppression is widely achieved.
- Published
- 2019
- Full Text
- View/download PDF